Details for Patent: 8,067,427

Which drugs does patent 8,067,427 protect, and when does it expire?

Patent 8,067,427 protects CAPRELSA and is included in one NDA.

This patent has forty patent family members in thirty-three countries.

Summary for Patent: 8,067,427

Title:	Pharmaceutical compositions comprising ZD6474
Abstract:	A pharmaceutical composition comprising ZD6474 or a pharmaceutically acceptable salt thereof, a brittle diluent and a second diluent which is practically insoluble and has ductile compression properties.
Inventor(s):	Stott; Paul William (Wilmington, DE)
Assignee:	AstraZeneca AB (Sodertajle, SE)
Application Number:	11/596,979
Patent Claim Types: see list of patent claims	Composition; Compound;

Drugs Protected by US Patent 8,067,427

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Genzyme Corp	CAPRELSA	vandetanib	TABLET;ORAL	022405-001	Apr 6, 2011		RX	Yes	No			Y
Genzyme Corp	CAPRELSA	vandetanib	TABLET;ORAL	022405-002	Apr 6, 2011		RX	Yes	Yes			Y

Foreign Priority and PCT Information for Patent: 8,067,427

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	0411378.3	May 21, 2004

PCT Information
PCT Filed	May 18, 2005	PCT Application Number:	PCT/GB2005/001931
PCT Publication Date:	December 01, 2005	PCT Publication Number:	WO2005/112934

International Family Members for US Patent 8,067,427

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	049059
Argentina	110045
Austria	E439841
Australia	2005244650
Brazil	PI0511253